The utility of this model as a platform for 12-LOX inhibitor testing was confirmed in our multiple low-dose STZ studies, which showed that VLX-1005 administration to B6.hALOX12 mice precluded hyperglycemia, whereas WT controls developed hyperglycemia over time. This evidence concerns the gene ALOX15 and Hyperglycemia.